Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
A. Galkin (San Diego, United States of America), R. Sitapara (San Diego, United States of America), B. Clemons (San Diego, United States of America), E. Garcia (San Diego, United States of America), M. Kennedy (San Diego, United States of America), L. Carter (San Diego, United States of America), D. Slee (San Diego, United States of America), L. Salter-Cid (San Diego, United States of America), L. Zisman (San Diego, United States of America)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Session: Pathophysiology of pulmonary hypertension
Session type: E-poster session
Number: 3550
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Galkin (San Diego, United States of America), R. Sitapara (San Diego, United States of America), B. Clemons (San Diego, United States of America), E. Garcia (San Diego, United States of America), M. Kennedy (San Diego, United States of America), L. Carter (San Diego, United States of America), D. Slee (San Diego, United States of America), L. Salter-Cid (San Diego, United States of America), L. Zisman (San Diego, United States of America). Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH). 3550
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: